EyePoint Pharmaceuticals, Inc. (EYPT) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 16 Buy, 2 Hold.
The consensus price target is $37.50 (low: $36.00, high: $39.00), representing an upside of 161.5% from the current price $14.34.
Analysts estimate Earnings Per Share (EPS) of $-2.17 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.32 vs est $-2.17 (missed -6.8%). 2025: actual $-3.17 vs est $-3.03 (missed -4.5%). Analyst accuracy: 95%.
EYPT Stock — 12-Month Price Forecast
$37.50
▲ +161.51% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for EyePoint Pharmaceuticals, Inc., the average price target is $37.50, with a high forecast of $39.00, and a low forecast of $36.00.
The average price target represents a +161.51% change from the last price of $14.34.
Highest Price Target
$39.00
Average Price Target
$37.50
Lowest Price Target
$36.00
EYPT Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to EyePoint Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — EYPT
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.32
vs Est –$2.17
▼ 6.4% off
2025
Actual –$3.17
vs Est –$3.03
▼ 4.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — EYPT
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.043B
vs Est $0.043B
▲ 1.7% off
2025
Actual $0.031B
vs Est $0.032B
▼ 1.3% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
